Trial intelligence / Profile preview

Pyrotinib added to CDK4/6 inhibitor plus aromatase inhibitor in HR-positive HER2-low advanced breast cancer with stable disease after first-line therapy

ChiCTR2300078928Phase 4Recruiting

Sponsor

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

Start

Dec 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1